Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Should be normal accumulation this week, perhaps a light pop above .08 cents unbelievable, because this meeting in New York with Cavendish Group, will take time to fully unfold.
But, for them to drop 20 million into this would not be a big surprise. If that happens as a Grant, the stock would probably only double. But with the Michael J Fox Foundation completing Eltoprozine studies this Summer that's exciting to know.
Give you and all of us more time to accumulate many millions
more of shares before its in the .20 - .30 cent range. Better to buy now there is plenty of proof.
"Final results are expected by summer 2014. may rapidly lead to clinical application of the findings."
Pharmacological Targeting of the 5-HT1, A2A and NMDA Receptors: An Integrative Approach to Dyskinesia
Objective/Rationale:
The glutamate, serotonin and adenosine systems are interesting targets for pharmacological therapies in Parkinson´s disease. However, interventions addressed at single systems have so far produced limited results. Indeed, the alterations induced in the human brain by the loss of dopamine neurons are complex and affect the function of several brain systems.
In this project we intend to counteract dyskinesia and worsening of motor function by co-targeting the above systems, which is expected to produce a better outcome than individual interventions.
Project Description:
We will use drugs that can be used on humans. The serotonin 5-HT1 receptor against Eltoprazine will be administered with the A2A receptor antagonist Preladenant or the NMDA receptor antagonist Amantadine to counteract dyskinesia and worsening of the therapeutic effect of L-DOPA in the pre-clinical model of Parkinson´s disease. Moreover, the most promising approach will be tested, during the second year, in the MPTP-treated model, the gold-standard model for pre-clinical studies of Parkinson´s disease.
Relevance to Diagnosis/Treatment of Parkinson’s Disease:
The appearance of dyskinesia represents a serious limitation for management of motor symptoms in advanced stages of disease. In fact, Amantadine is the only compound used in patients, but it has limited efficacy and side effects. There is, therefore, a high need for improved pharmacological treatment that can control dyskinesia while leaving intact the therapeutic effect of L-DOPA.
Anticipated Outcome:
According to our preliminary results, the proposed combined therapies are expected to produce improved antidyskinetic effects, and amelioration of motor symptoms. The advantage of this approach relies on the fact that medications in advanced stage of clinical development will be used. Therefore, this project may rapidly lead to clinical application of the findings.
INTERIM PROGRESS REPORT
We have completed experiments in parkinsonian dyskinetic preclinical models. Results have so far suggested that co-administration of the A2A receptor antagonist Preladenant and the 5-HT1 receptor agonist Eltoprazine is highly effective in suppressing already established levodopa-induced dyskinesia, while easing the motor impairments in a model of Parkinson´s disease. This approach is currently being tested in MPTP-treated models. Further experiments in the initial model are also ongoing to address whether this treatment can prevent development of dyskinesia when given starting from the first levodopa dose. Final results are expected by summer 2014.
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1030
RESEARCHERS
Urmas Arumäe, PhD
Helsinki , Finland
Mart Saarma, PhD
Helsinki , Finland
Other Grants awarded to this researcher:
CDNF a novel conserved neurotrophic factor that protects midbrain dopaminergic neurons in vivo
Effects of Recombinant CDNF Protein in Alpha-synuclein Model of Parkinson's Disease in Pre-Clinical Models
CDNF - A Novel Conserved Neurotrophic Factor that Protects Midbrain Dopaminergic Neurons in vivo
CDNF (Cerebral Dopamine Neurotrophic Factor) for Therapy of Parkinson's Disease
Raimo Kalevi Tuominen, MD, PhD
Helsinki , Finland
Institution
Institute of Biotechnology, University of Helsinki, University of Helsinki
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=927
Since MANF is protected, I would assume a short version of it is as well. It would be a question for the CEO likely via Twitter.
This story is from 2010 such promise, where is the follow up?
Moving very slowly, my previous post 2012, so in 2014 we are due for some more updates on research outside MJFF organization.
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=644
INTERIM PROGRESS REPORT
MANF is one of two new molecules (the other is CDNF) currently in pre-clinical development for the treatment of Parkinson's disease. In a recently completed pre-clinical model of Parkinson's disease funded by MJFF, MANF corrected the neurological deficits when it was given immediately after the animals became sick. MANF also corrected the neurological deficits when it was given three weeks after the models became sick. This means that MANF is able to prevent the death of healthy dopaminergic neurons, but also MANF can save dopaminergic neurons that are already dying. How do these results apply to human patients? The results suggest that in patients newly diagnosed with Parkinson's disease MANF might be able to save those dopaminergic neurons that are sick and dying, but not yet dead. These patients will likely get better sooner, and their recovery will also last for a longer time. It is much too soon to predict whether MANF will be able to cure Parkinson's disease. MANF is certainly one of the most promising molecules currently in development to treat this debilitating disease.
cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death
Grant 2012
GRANT ABSTRACT
Objective/Rationale:
Parkinson's disease (PD) is caused by the degeneration of certain dopaminergic neurons in the brain. Neurotrophic factors like GDNF protect dopaminergic neurons from degenerating in animal models of PD, but have so far not worked in clinical trials. MANF is a new neurotrophic factor that is strongly indicated for PD. This project will compare MANF and GDNF in new animal models of PD to determine if MANF is likely to be more effective than GDNF in clinical trials for PD.
Project Description:
We will first optimize the MANF-derived peptide in vitro to find out its minimal size, effective concentration and to exclude the adverse effects on the healthy cells. The optimized peptide will then be tested on the 6-hydroxydopamine (6-OHDA) neuroprotection model of Parkinson’s disease. The peptide or Glial Cell Line-Derived Neurotrophic Factor (GDNF) as a positive control will be injected to the striata of the models, followed by 6-OHDA injection 6 h later. 2 and 4 weeks later the amphetamine-induced rotational behavior of the models will be tested to reveal the extent of the functional damage of the dopaminergic system. At the end of the experiment, the brain sections will be stained with the tyrosine hydroxylase antibodies to reveal the extent of the histological damage of the dopaminergic system.
Relevance to Diagnosis/Treatment of Parkinson’s Disease:
As the small-size peptide spreads better in the brain parenchyma than the larger proteins, it should be more efficient than the full-length MANF protein. Also, as MANF can efficiently prevent cell death intracellularly, the cell-penetrating properties of the MANF-derived peptide could attenuate its neurotrophic efficiency.
INTERIM PROGRESS REPORT
We found that the peptide can be reduced up to tetrapeptide that still has potent neuroprotective and cell-penetrating properties. The tetrapeptide dose-dependently promoted survival of cultured embryonic pre-clinical dopaminergic neurons and spontaneously penetrated the neurons, but had any obvious effect on the cultured non-neuronal cells. In the proof-of-principle in vivo neuroprotective experiment, the tetrapeptide effectively counteracted the Parkinsonian symptoms caused by 6-hydroxydopamine: it significantly reduced the amphetamine-induced rotation of the models. The effective dose of the peptide for in vivo experiments was found.
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=927
Pharma in China Being Held to Higher Standard, Says Greg Scott, ChinaBio
http://mendelspod.com/podcast/pharma-china-being-held-higher-standard-says-greg-scott-chinabio
They might find a credible partner with a background
in China of being a Fair partner. A known Bio-Tech Giant in China, who because of world opinion must maintain higher standards.
That would be one solution - Find the Golden Goose
who is also honest.
China, larger market than USA, Good place to "make a deal"
and get this doggy bow-wow- with fleas, "uplisted".
Riskreturn no bashing the company here.
I was referring to a Chinese company that is opening its doors to AMBS.
Outstanding Jembers, AMBS could pay a "fee" get setup in China
big time.
Really! We will be at ChinaBio? What is that.
Yeh but right now? its .05 cent, vs 50 cent.
Sorry to squash your party,that article is 2012.
Yes but article mentioned is 2012.
The Dogs are barking GC.
Get an agreement.
Overexpression of MANF in stably transfected N2A cells and its inhibition of ER stress-mediated apoptosis
Author(s): CHEN Zuo, LI Chengjin, YANG Wen, CHENG Li, AN Ran, DU Jian, SHEN Yujun, FENG Lijie, SHEN Yuxian
Journal: Acta Universitatis Medicinalis Anhui , Year 2013 , Issue 11 , Page 1308-1311,1312
Keyword: MANF%transfection%ER stress%neural protection;
http://caod.oriprobe.com/articles/40359347/Overexpression_of_MANF_in_stably_transfected_N2A_cells_and_its_inhibit.htm
Article Title: MANF inhibits tau hyperphosphorylation in cultured neuronal cells
Author: LI Jing; WANG Tao; SHEN Yu-jun; FANG Sheng-yun; SHEN Yu-xian
Journal Information: Chinese Pharmacological Bulletin Year 2012, Issue 8, Page 1111-1115
Price: US$29.95
Chinese Pharmacological Bulletin Year 2012, Issue 8, Page 1111-1115
MANF in Chinese Search
http://caod.oriprobe.com/articles/found.htm?keyword=MANF&package=&key_author=&key_qkname=&key_year=&key_volumn=&key_issue=
MANF inhibits tau hyperphosphorylation in cultured neuronal cells
LI Jing, WANG Tao, SHEN Yu-jun, FANG Sheng-yun, SHEN Yu-xian
Chinese Pharmacological Bulletin Year 2012, Issue 8, Page 1111-1115
What is the ISSN number of this report
MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells
We can only hope: Pfizer for LymPro - Novartis for MANF for Diabetes
Now thats the spirit, a presentation at the wealthiest family group
or lets say one of the family groups, Cavendish for Ethical investing in technology and events that can help society.
Well a grant or investment now would be SOOOOOO cheap for them.
Bottom Dwellers that they are, they are very wealthy.
I"ve come to realize how much stock that GC sold out
it has been absolutely ludicrous to sell 1-2 million shares
for 10,000 in 2012. Like I have said all along GC needs to be in the back seat marketing, and a real CEO needs to step in that
can get the train rocking big. The amount of money spent to date and the constant babble nonesense between the board and the CEO
Geez get the Ball in the HOLE would you.
B J Borman
Dr. Bormann has had a distinguished and extensive career in the pharmaceutical industry. Most recently, she served as Senior Vice President and Worldwide Head of Therapeutic Alliances and Strategic Partnerships at Boehringer Ingelheim Pharmaceuticals Inc. Prior to that, she held the position of Vice President, Strategic Alliances, at Pfizer Inc.
http://www.prnewswire.com/news-releases/biolinerx-appoints-b-j-bormann-to-board-of-directors-220167431.html
Several scientists who work in the area of Alzheimer's Disease and neurodegenertion at Pfizer
Inc are familar with the Pilot Study of the Lymphocyte Proliferation Test (LymPro Test) for the
diagnosis of Alzheimer's
disease (AD)......
Oh and DVD's on how to Dilute a BB:OTC from 70million to 700 million its a real art.
Pens - Paper - Tshirts - Hats
Can we have these please?
AMBS - LymPro® - Hat Designs
I would buy a T-Shirt and Hat or two from AMBS if they had some decent ones on their web site to help pay the light bills.
Pfizer - and Lympro from barcode27 - Brilliant Find.
Must read this post.
Dear NIG Reviewer,
Several scientists who work in the area of Alzheimer's Disease and neurodegenertion at Pfizer
Inc are familar with the Pilot Study of the Lymphocyte Proliferation Test (LymPro Test) for the diagnosis of Alzheimer's
disease (AD)......
Current Milestones & Catalysts
LymPro
• Pilot clinical performance data (1H-14);
• Retrospective / prognostic 9 year patient record clinical study (1H-14)
• Clinical Performance studies to support CLIA registration (1H-14)
• Commercial Launch as a Laboratory-Developed Test (“LDT”) under CLIA (2H- 2014)
Eltoprazine
• Evaluate best indication for commercial development (1H/14)
• Initiate Phase 2b Clinical Trial (1H/14)
• MJFF Grant Funding (FY-14)
MANF
• Retinitis Pigmentosa: functional genetic mouse model (1H-14)
• Parkinson’s disease: CED delivery data w/Renishaw (1H-14)
• Preliminary systemic toxicology (PK/PD relationship) (1H-14)
• Wolfram Syndrome enablement (Diabetes)
• Functional Data (RP)
That might be true for a few hours or days, but you don't get invited to do a presentation very easily, this is a very select group who can throw around 20 million like your quarters in your pocket.
Whoops, Cavendish Group caught wind of this.
Sure would like to see Cavendish/Bill & Melinda Amarantus BioScience
Conference Call was done in standard "NASDAQ" type style,
with the legal, and accounting interests in the room and
technical team. Also CEO talking not just CFO.
So as meetings go and information spillage pretty good considering the rules and regulations that must be met and
withheld. Sounds like the stock needs to upgrade to .24 cents
just to get the skids ready.
At begging of Meeting the Sales/Marketing director could not attend this meeting as he was fully engaged with client potential at the NIS meeting today. The Congressman overseas $1Trillion in Spending
GC said today.
House Appropriations Committee Chairman Harold Rogers, R-Ky<< Possibly
Get on the Money Train and Spike this Stock to a buck.
Standard jargon, financial warnings in all small companies.
Who is posting this JUNK when every investor thats over 2yrs old
knows this stuff by heart. Ho ho ho Here comes the Billion Dollar Money Train CHOOOOOO CHOOOOOO
This is perfect, just what we want in a Bio-Tech.
Nothing wrong with increasing spending and costs when drugs are
on the way. Thanks for Pointing out the obvious again.
Bio-Techs spend Billions to get to market average is 100 million per drug maybe that's low.
Yes great buying time here. When its %300 higher you would be wishing you had loaded up. Too much going on now and too much financing in place.
dsw, if you want I can submit your posts for legal review
Why thank you all my tweet Brothers and Sisters. Perhaps it's the best thing to tweet to greatness .
Glad that all is well and here's to
GC for driving fast in a cluttered roadway of obstacles. Between Lympro, Eltoprozine, and MANF
WE CAN TRADE AT 300 million market Cap Now about .40 cents
Really you like a tweeting CEO
HOW ABOUT a professional
With impeccable credentials
Who does not Tweet for a living
This company will gain momentum
When the penny day traders and slime investment bankers are bought out at .18cents a share geez people wake up.
What tweet by rook or by crook
A CEO THAT follows a IHub Board
Instead of running a company